Pfizer Corporation

Other

Patrick Stephen Johnson

Justin Stephen Bryans

Thomas Ryckmans

Alan Stobie

Kevin Neil Dack

Lee Richard Roberts

Sarah Elizabeth Skerratt

Paul Anthony Bradley

Jingrong Jean Cui

Andrew Douglas Baxter

Cynthia Louise Palmer

Mark Edward Bunnage

David James Rawson

Judith Gail Deal

Russell Andrew Lewthwaite

Hong Shen

Ted William Johnson

Mingying He

Phuong Thi Quy Le

Andrew Simon Cook

Julie Newman

Danlin Gu

Toby James Underwood

Robert Duncan Armour

Kevin Nell Dack

Phuong Thi Le

Helen Janet Mason

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein. 

Alkoxy-substituted 2-aminopyridines as ALK inhibitors

The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y' are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.

Compounds useful in therapy

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein:

Triazolyl piperidine arginine vasopressin receptor modulators

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein

Triazolobenzodiazepines and their use as vasopressin antagonists

Triazole derivatives which inhibit vasopressin antagonistic activity

A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

Triazole compounds useful in therapy

Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein Rand Rindependently represent H, Calkyl, Ccycloalkyl, or halogen; Rrepresents Calkyl, CFor aryl; a represents 1 or 2; R, R, Rand Rindependently represent H, Calkyl, Calkyloxy, CN or halogen, or Rand R, or Rand R, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CHor O; Rrepresents H, CN or halo provided that, when X represents N, Ris absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.

1H-pyrazoles useful in therapy

A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

The invention provides compounds of formula (I), the pharmaceutically acceptable salts and solvates thereof, wherein A, B, R, R, and Rare as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof as vasopressin Vantagonists.

Growing community of inventors

Sandwich, United Kingdom

Patrick Stephen Johnson